Chardan Capital Keeps Buy on SAB Biotherapeutics, Raises PT to $14

Wednesday, Mar 11, 2026 2:46 pm ET1min read
SABS--

Chardan Capital Keeps Buy on SAB Biotherapeutics, Raises PT to $14

Chardan Capital Keeps Buy on SAB Biotherapeutics, Raises PT to $14

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet